CNS Pharmaceuticals (CNSP) Cash & Equivalents (2018 - 2025)

CNS Pharmaceuticals (CNSP) has 8 years of Cash & Equivalents data on file, last reported at $7.2 million in Q4 2025.

• Quarterly Cash & Equivalents rose 11.45% year-over-year to $7.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.2 million (up 11.45% YoY) and the FY2025 annual result came in at $7.2 million, up 11.45% from the prior year.
• Cash & Equivalents declined to $7.2 million in Q4 2025, from $9.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.0 million in Q1 2025 to a low of $548721.0 in Q4 2023.
• A 5-year average of $6.9 million and a median of $7.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 94.54% — and 2025, when it soared 1500.49%.
• Tracing CNSP's Cash & Equivalents over 5 years: stood at $5.0 million in 2021, then soared by 100.93% to $10.1 million in 2022, then plunged by 94.54% to $548721.0 in 2023, then soared by 1077.53% to $6.5 million in 2024, then climbed by 11.45% to $7.2 million in 2025.
• The last three Cash & Equivalents figures came in at $7.2 million (Q4 2025), $9.9 million (Q3 2025), and $12.1 million (Q2 2025), per Business Quant data.